PGE<sub>2</sub>‐EP<sub>2</sub>/EP<sub>4</sub> axis: A new perspective on cancer immunotherapy.
- Published in:
- Medcomm: Oncology, 2024, v. 3, n. 3, p. 1, doi. 10.1002/mog2.90
- By:
- Publication type:
- Article
Works matching IS 27696448 AND DT 2024 AND VI 3 AND IP 3
Results: 10
1
2
Extensive infiltration of CD8<sup>+</sup> T cells and M1 macrophages is beneficial for multiple cancer patients undergoing chemotherapy.
- Published in:
- Medcomm: Oncology, 2024, v. 3, n. 3, p. 1, doi. 10.1002/mog2.89
- By:
- Publication type:
- Article
3
Deciphering transcriptional bursts and enhancer dynamics: Advancing cancer therapeutics through single‐cell global run‐on sequencing.
- Published in:
- Medcomm: Oncology, 2024, v. 3, n. 3, p. 1, doi. 10.1002/mog2.88
- By:
- Publication type:
- Article
4
CoCl<sub>2</sub>‐induced glioma hypoxia environment enhances CD47‐SIRPα to promote tumor immune evasion.
- Published in:
- Medcomm: Oncology, 2024, v. 3, n. 3, p. 1, doi. 10.1002/mog2.87
- By:
- Publication type:
- Article
5
The prognostic value of microRNA‐200 family expression in digestive system tumors: A meta‐analysis and validation.
- Published in:
- Medcomm: Oncology, 2024, v. 3, n. 3, p. 1, doi. 10.1002/mog2.86
- By:
- Publication type:
- Article
6
Enhancing cancer immunotherapy and antiangiogenic therapy by regulating gut microbes: Opportunities and challenges.
- Published in:
- Medcomm: Oncology, 2024, v. 3, n. 3, p. 1, doi. 10.1002/mog2.85
- By:
- Publication type:
- Article
7
Early prediction of neoadjuvant chemotherapy efficacy for mass breast cancer based on dynamic contrast‐enhanced magnetic resonance imaging radiomics.
- Published in:
- Medcomm: Oncology, 2024, v. 3, n. 3, p. 1, doi. 10.1002/mog2.84
- By:
- Publication type:
- Article
8
Alanyl‐tRNA synthetase AARS1: A novel lactate sensor and lactyltransferase mediating p53 lactylation and tumorigenesis.
- Published in:
- Medcomm: Oncology, 2024, v. 3, n. 3, p. 1, doi. 10.1002/mog2.83
- By:
- Publication type:
- Article
9
Next‐generation sequencing identifies that protein tyrosine phosphatase receptor type D mutation is favorable to immunotherapy in human cancer.
- Published in:
- Medcomm: Oncology, 2024, v. 3, n. 3, p. 1, doi. 10.1002/mog2.80
- By:
- Publication type:
- Article
10
Issue Information.
- Published in:
- Medcomm: Oncology, 2024, v. 3, n. 3, p. 1, doi. 10.1002/mog2.36
- Publication type:
- Article